Health & Fitness

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient recruitment for the phase 1 trial will begin soon (NCT06913608). The phase 1 clinical trial will evaluate the safety and efficacy of CLBR001 + SWI019 in patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis, with the potential to expand to other indications in the future.

from Top Health News -- ScienceDaily https://ift.tt/gj3pLXf

A study has shown that Europe has adapted better to low temperatures than to high temperatures over the last two decades. The relative risk of mortality at the coldest temperatures has decreased by 2% per year since 2003, while the risk from extreme heat has only fallen by 1% per year.

from Top Health News -- ScienceDaily https://ift.tt/KEzBUCi